Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-γ activity in 3T3-L1 adipocytes

Biochemical and Biophysical Research Communications

Volumn 328, Issue 2, 2005, Pages 484-490

  Inukai, Kouichi ^a   Watanabe, Masaki ^a   Nakashima, Youhei ^a   Takata, Nobuki ^a   Isoyama, Ai ^a   Sawa, Takahiro ^a   Kurihara, Susumu ^a   Awata, Takuya ^a   Katayama, Shigehiro ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

3T3 L1 adipocytes; Glimepiride; PPAR

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; GLIBENCLAMIDE; GLIMEPIRIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TRIACYLGLYCEROL;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL STIMULATION; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG EFFECT; ENZYME PHOSPHORYLATION; FIBROBLAST; GENE ACTIVITY; GENETIC TRANSCRIPTION; INSULIN RESISTANCE; LIPID ANALYSIS; MARKER GENE; MOUSE; MYOBLAST; NONHUMAN; OBSERVATION; PRIORITY JOURNAL;

EID: 13444311744     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.12.190     Document Type: Article

References (29)

1. C. Rosak The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents J. Diabetes Complicat. 16 2002 123 132
2. G. Muller, and S. Wied The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation and dephosphorylation in insulin-resistant rat adipocytes in vitro Diabetes 42 1993 1852 1867
3. A. Haupt, C. Kausch, D. Dahl, O. Bachmann, M. Stumvoll, H.U. Haring, and S. Matthaei Effect of glimepiride on insulin-stimulated glycogen synthesis in cultured human skeletal muscle cells; a comparison to glibenclamide Diabetes Care 25 2002 2129 2132
4. J. Rosenstock, J. Schneider, E. Samols, and D.B. Mushmore Glimepiride, a new once-daily sulfonylurea Diabetes Care 19 1996 1194 1199
5. R. Rosskamp, K. Wernicke-Panten, and E. Draeger Clinical profile of the novel sulfonylurea glimepiride Diabetes Res. Clin. Pract. 31 1996 S33 S42
6. K. Inukai, M. Watanabe, Y. Nakashima, T. Sawa, N. Takata, M. Tanaka, H. Kashiwabara, K. Yokota, M. Suzuki, S. Kurihara, T. Awata, S. Katayama, Efficacy of glimepiride in Japanese type 2 diabetic subjects, Diabetes Res. Clin. Pract. (2005) (in press)
7. H.E. Clark, and D.R. Mattews The effects of glimepiride on pancreatic β-cell function under hyperglycemic clamp and hyper-insulinemic, euglycemic clamp conditions in non-insulin-dependent diabetes mellitus Horm. Metab. Res. 28 1996 445 450
8. G. Muller The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug amaryl Mol. Med. 6 2000 907 933
9. J.M. Lehmann, L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Willson, and S.A. Kliewer An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor-γ J. Biol. Chem. 270 1995 12953 12956
10. E. Hu, J.B. Kim, P. Sarraf, and B.M. Spiegelman Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ Science 274 1996 2100 2103
11. G. Lazennec, L. Canaple, D. Saugy, and W. Wahli Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators Mol. Endocrinol. 14 2000 1962 1975
12. B. Zhang, J. Berger, E. Hu, D. Szalkowski, S. White-Carrington, B.M. Spiegelman, and D.E. Moller Negative regulation of peroxisome proliferator-activated receptor-γ gene expression contributes to tumor necrosis factor-α Mol. Endocrinol. 10 1996 1457 1466
13. S.E. Rosenbaum, and A.S. Greenberg The short- and long-term effects of tumor necrosis factor-α and BRL49653 on peroxisome proliferator-activated receptor (PPAR) γ2 gene expression and other adipocyte genes Mol. Endocrinol. 12 1998 1150 1160
14. M. Watanabe, K. Inukai, H. Katagiri, T. Awata, Y. Oka, and S. Katayama Regulation of PPARγ transcriptional activity in 3T3-L1 adipocytes Biochem. Biophys. Res. Commun. 300 2003 429 436
15. S.R. Ross, R.A. Graves, A. Greenstein, K.A. Platt, H.-L. Shyu, B. Mellovitz, and B.M. Spiegelman A fat-specific enhancer is the primary determinant of gene expression for adipocyte P2 in vivo Proc. Natl. Acad. Sci. USA 87 1990 9590 9594
16. M. Iwaki, M. Matsuda, N. Maeda, T. Funahashi, Y. Matsuzawa, M. Makishima, and I. Shimomura Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors Diabetes 52 2003 1655 1663
17. H. Katagiri, T. Asano, H. Ishihara, K. Inukai, Y. Shibasaki, M. Kikuchi, Y. Yazaki, and Y. Oka Overexpression of catalytic subunit 110α of phosphatidylinositol 3-kinase increases glucose transport activity with translocation of glucose transporter in 3T3-L1 adipocytes J. Biol. Chem. 271 1996 16987 16990
18. B.H. Jones, J.H. Kim, M.B. Zemel, R.P. Woychik, E.J. Michaud, W.O. Wilkison, and N. Moustaid Upregulation of adipocyte metabolism by agouti protein: possible paracrine actions in yellow mouse obesity Am. J. Physiol. 270 1996 E192 E196
19. N. Maeda, I. Shimomura, K. Kishida, H. Nishizawa, M. Matsuda, H. Nagaretani, N. Furuyama, H. Kondo, M. Takahashi, Y. Arita, R. Komuro, N. Ouchi, S. Kihara, Y. Tochino, K. Okutomi, M. Horie, S. Takeda, T. Aoyama, T. Funahashi, and Y. Matsuzawa Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 Nat. Med. 8 2002 731 737
20. P. Tontonoz, E. Hu, and B.M. Spiegelman Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor Cell 79 1994 1147 1156
21. G. Zhou, R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M.F. Hirshman, L.J. Goodyear, and D.E. Moller Role of AMP-activated protein kinase in mechanism of metformin action J. Clin. Invest. 108 2001 1167 1174
22. S.N. Jakobsen, D.G. Hardie, N. Morrice, and H.E. Tornqvist 5′-AMP-activated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4-carboxamide riboside J. Biol. Chem. 276 2001 46912 46916
23. L. Aguilar-Bryan, C.G. Nichols, S.W. Wechsler, J.P. Clement IV, A.E. Boyd III, G. Gonzalez, H. Herrera-Sosa, K. Nguy, J. Bryan, and D.A. Nelson Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion Science 268 1995 423 426
24. M. Schupp, J. Janke, R. Clasen, T. Unger, and U. Kintscher Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity Circulation 109 2004 2054 2057
25. S.C. Benson, H.A. Pershadsingh, C.I. Ho, A. Chittiboyina, P. Desai, M. Pravenec, N. Qi, J. Wang, M.A. Avery, and T.W. Kurtz Identification of Telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity Hypertension 43 2004 1 10
26. L.A. Velloso, F. Folli, X.J. Sun, M.F. White, and M.J.A. Saad Cross-talk between the insulin and angiotensin signaling systems Proc. Natl. Acad. Sci. USA 93 1996 12490 12495
27. H.D. Langtry, and J.A. Balfour Glimepiride: a review of its use in the management of type 2 diabetes mellitus Drugs 55 1998 563 584
28. T. Tsunekawa, T. Hayashi, Y. Suzuki, H. Matsu-Hirai, H. Kano, A. Fukatsu, N. Nomura, A. Miyazaki, and A. Iguchi Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects Diabetes Care 26 2003 285 289
29. T.P. Combs, J.A. Wagner, J. Berger, T. Doebber, W.J. Wang, B.B. Zang, M. Taren, A.H. Berg, S. O'Rahilly, D.B. Savage, K. Chatterjee, S. Weiss, P.J. Larson, K.M. Gottesdiener, B.J. Gertz, M.J. Charron, P.E. Scherer, and D.E. Moller Induction of adipocyte complement-related protein of 30 kilodalton by PPARgamma agonists: a potential mechanism of insulin sensitization Endocrinology 143 2002 998 1007